Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3310847 | 0.86 | KMT2A (0.79) | MAPTLMNAMAPK1NPSR1KMT2A | |
| SCHEMBL3311114 | 0.82 | KMT2A (0.68) | KMT2ACA1MAOAMAOB | |
| SCHEMBL3314492 | 0.81 | KMT2A (0.67) | KMT2ACA1MAOAMAOB | |
| SCHEMBL3310647 | 0.81 | MAOA (0.69) | KMT2ACA1MAOAMAOB | |
| SCHEMBL3310651 | 0.81 | KMT2A (0.67) | NPSR1KMT2ACA1MAOAMAOB | |
| SCHEMBL3314103 | 0.80 | ALDH1A1 (0.70) | HTTMAPTLMNANPSR1KMT2A | |
| SCHEMBL3313107 | 0.78 | KMT2A (0.62) | HTTMAPTKMT2ACA1MAOA | |
| SCHEMBL3313102 | 0.76 | MAOA (0.61) | HTTMAPTLMNAMAPK1NPSR1 | |
| SCHEMBL23052467 | 0.75 | MAOB (0.71) | KMT2ACA1MAOAMAOB | |
| SCHEMBL28260653 | 0.75 | CA1 (0.71) | KMT2ACA1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2008045663-A2 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTIINFLAMMATORY AGENTS | KALYPSYS, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105729-A1 | ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS | PDE4A, PDE4B, PDE4C | HTT 3164/4885MAPT 4438/4885LMNA 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.